Manheum Na
Head, New Biological Drug Department Celltrion
Seminars
Thursday 11th June 2026
CT-P72/ABP-102: A dual affinity engineered HER2/CD3 tetravalent bispecific antibody with potential to overcome therapeutic barriers in HER2 high tumors with distinct potency, safety, and selectivity
3:30 pm
- CT-P72/ABP-102 bound specifically to human and cynomolgus macaque HER2 and CD3, and exhibited lower binding to both HER2 and CD3 compared to its parental antibody ABP 10.0
- CT-P72/ABP-102 demonstrated activity in T-cell activation, PBMC-mediated cytotoxicity, and cytokine release experiments comparable to the parental bispecific antibody with HER2 high-expressing tumor target cells but exhibited reduced activity with HER2-low tumor target cells
- CT-P72/ABP-102 was well tolerated, with the NOAEL determined to be 80 mg/kg when administered twice a week for 4 weeks (total of 8 doses).
![Celltrion[1]](https://worldbispecifics-tce-kr.com/wp-content/uploads/sites/266/2026/02/Celltrion1-300x300.png "Celltrion[1]")